A Phase 2 interventional study of DR-1031 and Seasonale® in Breakthrough Bleeding, sponsored by Duramed Research. Completed at 50 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-26.
Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.
Among the 43 studies in Metrorrhagia with a site in United States, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2006, is the only one in phase 2, and was the 4th registered.
153 studies on the registry are indexed under Metrorrhagia; 35 are open to participants now.
Browse Metrorrhagia studies →8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+ · Women only
Channel Medsystems · Sites in United States
Ages 25+ · Women only
Eastern Virginia Medical School · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
UConn Health · Sites in United States
Ages 18+ · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Metrorrhagia studies recruiting now, 9 (45%) set no upper age limit and 11 (55%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 567 is above the median of 100 across 115 interventional studies indexed under Metrorrhagia.
Median enrollment 60 across the 40 interventional studies, 300 across the 3 observational. Of the 31 that completed or were terminated, 17 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Duramed Research, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 1 study filed under Metrorrhagia — fewer than ten, so there is no comparison to draw.
2 of the studies in Metrorrhagia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653400Icahn School of Medicine at Mount SinaiCombined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy | 2026-12-31 |
| NCT07290517Indiana UniversityAssessing Pain and Effectiveness of Carevix Device for IUD Insertions | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Metrorrhagia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 4-arm study to evaluate and compare bleeding patterns between three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary
This Phase 2, prospective, multicenter, double-blinded, randomized study is designed to evaluate and compare bleeding patterns in women using one of three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive.
Patients who meet all study entrance criteria will be randomly assigned to one of four treatment groups,
The overall study duration will be approximately 9 months; this will include a screening period of approximately 4 weeks, a run-in period of 4 weeks, a treatment period of approximately 6 months (two,91-day cycles) and a final study visit occurring 14-21 days after completion of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
Drug: DR-1031 · Drug: Portia®
21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
Drug: DR-1031 · Drug: Portia®
21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
Drug: DR-1031 · Drug: Portia®
84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
Drug: Seasonale® · Drug: Portia®
Drug pages: Levonorgestrel · Ethinyl Estradiol
Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
Also known as: levonorgestrel/ethinyl estradiol, Quartette®
84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
Also known as: levonorgestrel/ethinyl estradiol
Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Also known as: levonorgestrel/ethinyl estradiol
Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)
Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.
Time frame: Day 1-84
Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)
Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.
Time frame: Day 92-176
Days With Bleeding During Active Cycle 1 (Day 1-84)
Bleeding is defined as a flow heavy enough to require sanitary protection.
Time frame: Day 1-84
Days With Bleeding During Active Cycle 2 (Day 92-176)
Bleeding is defined as a flow heavy enough to require sanitary protection.
Time frame: Day 92-176
Time to First Bleeding Day
Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection. Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.
Time frame: Day 1-84
Maximum Bleeding Severity During Active Cycle 1 (Day 1-84)
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity. See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.
Time frame: Day 1-84
Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)
Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.
Time frame: Day 85-91
Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)
Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.
Time frame: Day 177-183
Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
Time frame: Day 1-84
Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
Time frame: Day 92-176
Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
Time frame: Day 85-91
Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
Time frame: Day 177-183
Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
Time frame: Day 1-84
Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
Time frame: Day 92-176
| Milestone | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Started | 140 | 136 | 143 | 148 |
| Intent to treat (itt) population | 110 | 110 | 108 | 120 |
| Completed | 99 | 102 | 96 | 109 |
| Not completed | 41 | 34 | 47 | 39 |
| Withdrew: Did not meet protocol requirements | 1 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 2 | 4 | 9 | 7 |
| Withdrew: Withdrawal by subject | 10 | 6 | 8 | 12 |
| Withdrew: Adverse event | 10 | 5 | 12 | 8 |
| Withdrew: Participant pregnant | 0 | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 15 | 15 | 13 | 10 |
| Withdrew: Other | 3 | 3 | 1 | 0 |
Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84) | 13 (0 to 67) | 13.5 (0 to 65) | 15 (0 to 69) | 15 (0 to 56) |
Bleeding is defined as a flow heavy enough to require sanitary protection.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Days With Bleeding During Active Cycle 1 (Day 1-84) | 3.5 (0 to 24) | 2.5 (0 to 49) | 4 (0 to 47) | 2 (0 to 24) |
Bleeding is defined as a flow heavy enough to require sanitary protection.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Days With Bleeding During Active Cycle 2 (Day 92-176) | 1 (0 to 24) | 2 (0 to 49) | 1 (0 to 27) | 2 (0 to 23) |
Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection. Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.
No measurements were reported for this outcome.
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity. See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.
No measurements were reported for this outcome.
Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176) | 6 (0 to 74) | 7 (0 to 70) | 5 (0 to 74) | 6 (0 to 55) |
Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| 0 day | 14 | 28 | 25 | 27 |
| 1-3 days | 36 | 17 | 27 | 18 |
| 4-7 days | 59 | 63 | 54 | 75 |
Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| 0 day | 15 | 20 | 23 | 21 |
| 1-3 days | 32 | 32 | 26 | 24 |
| 4-7 days | 50 | 44 | 45 | 60 |
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Breast tenderness/pain | 58 | 57 | 50 | 64 |
| Headache | 83 | 84 | 86 | 92 |
| Bloating | 80 | 76 | 72 | 84 |
| Pelvic pain | 72 | 65 | 61 | 67 |
| Anxiety | 42 | 43 | 34 | 59 |
| Depression | 51 | 40 | 36 | 52 |
| Irritability | 72 | 69 | 66 | 78 |
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Breast tenderness/pain | 46 | 47 | 44 | 44 |
| Headache | 74 | 72 | 72 | 78 |
| Bloating | 64 | 64 | 57 | 70 |
| Pelvic pain | 58 | 57 | 45 | 57 |
| Anxiety | 40 | 40 | 31 | 47 |
| Depression | 41 | 39 | 30 | 44 |
| Irritability | 55 | 63 | 54 | 65 |
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Breast tenderness/pain | 33 | 28 | 17 | 33 |
| Headache | 57 | 50 | 57 | 50 |
| Bloating | 61 | 51 | 46 | 62 |
| Pelvic pain | 50 | 49 | 37 | 53 |
| Anxiety | 26 | 17 | 14 | 22 |
| Depression | 25 | 21 | 17 | 23 |
| Irritability | 44 | 43 | 23 | 36 |
Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.
| participants | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Breast tenderness/pain | 29 | 25 | 15 | 25 |
| Headache | 39 | 42 | 37 | 48 |
| Bloating | 51 | 53 | 38 | 60 |
| Pelvic pain | 52 | 42 | 31 | 51 |
| Anxiety | 21 | 22 | 13 | 22 |
| Depression | 18 | 21 | 15 | 17 |
| Irritability | 39 | 37 | 25 | 39 |
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84) | 0 (0 to 12) | 0 (0 to 19) | 0 (0 to 16) | 0 (0 to 21) |
Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
| days | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176) | 0 (0 to 11) | 0 (0 to 13) | 0 (0 to 8) | 0 (0 to 7) |
Collected over Day 1 up to Day 256 (longest treatment plus 14 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose DR-1031 | — | 1/140 (0.7%) | 61/140 (43.6%) |
| Midrange Dose DR-1031 | — | 2/136 (1.5%) | 44/136 (32.4%) |
| High Dose DR-1031 | — | 3/143 (2.1%) | 49/143 (34.3%) |
| Seasonale | — | 5/148 (3.4%) | 53/148 (35.8%) |
| Event | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/140 | 0/136 | 2/143 | 0/148 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/140 | 0/136 | 0/143 | 2/148 |
| CholecystitisHepatobiliary disorders | 0/140 | 1/136 | 0/143 | 0/148 |
| PyelonephritisInfections and infestations | 0/140 | 1/136 | 0/143 | 0/148 |
| Post procedural bile leakInjury, poisoning and procedural complications | 0/140 | 1/136 | 0/143 | 0/148 |
| HemiparesisNervous system disorders | 1/140 | 0/136 | 0/143 | 0/148 |
| HypoaesthesiaNervous system disorders | 1/140 | 0/136 | 0/143 | 0/148 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/140 | 0/136 | 1/143 | 0/148 |
| Small intestinal obstructionGastrointestinal disorders | 0/140 | 0/136 | 0/143 | 1/148 |
| VomitingGastrointestinal disorders | 0/140 | 0/136 | 0/143 | 1/148 |
| Event | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale |
|---|---|---|---|---|
| HeadacheNervous system disorders | 19/140 | 19/136 | 23/143 | 19/148 |
| NasopharyngitisInfections and infestations | 15/140 | 7/136 | 8/143 | 8/148 |
| DysmenorrhoeaReproductive system and breast disorders | 13/140 | 6/136 | 5/143 | 7/148 |
| SinusitisInfections and infestations | 10/140 | 6/136 | 2/143 | 6/148 |
| Upper respiratory tract infectionInfections and infestations | 9/140 | 7/136 | 5/143 | 9/148 |
| Weight increasedInvestigations | 6/140 | 4/136 | 9/143 | 8/148 |
| Urinary tract infectionInfections and infestations | 8/140 | 1/136 | 5/143 | 2/148 |
| MigraineNervous system disorders | 2/140 | 7/136 | 1/143 | 2/148 |
| Back painMusculoskeletal and connective tissue disorders | 7/140 | 7/136 | 5/143 | 6/148 |
ITT population
| Age Continuous(years) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 30.1 ± 6.88 | 30.5 ± 7.02 | 30.7 ± 7.61 | 30.6 ± 6.90 | 30.5 ± 7.08 |
| Sex: Female, Male(Participants) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Female | 110 | 110 | 108 | 120 | 448 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| African-American | 21 | 20 | 18 | 17 | 76 |
| Asian | 1 | 4 | 1 | 3 | 9 |
| Caucasian | 72 | 68 | 69 | 82 | 291 |
| Hispanic | 13 | 17 | 19 | 16 | 65 |
| Other | 3 | 1 | 1 | 2 | 7 |
| Weight(lbs) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 156.6 ± 28.84 | 153.6 ± 27.18 | 156.0 ± 30.79 | 151.9 ± 30.03 | 154.4 ± 29.22 |
| Body Mass Index(kg/m^2) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 26.6 ± 4.13 | 25.7 ± 4.24 | 26.0 ± 4.59 | 25.5 ± 4.41 | 25.9 ± 4.35 |
| Systolic Blood Pressure(mmHg) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 114.2 ± 10.74 | 114.4 ± 10.34 | 115.6 ± 9.31 | 112.8 ± 10.23 | 114.2 ± 10.19 |
| Diastolic Blood Pressure(mmHg) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 72.3 ± 8.85 | 72.9 ± 7.46 | 71.8 ± 7.72 | 71.4 ± 8.44 | 72.1 ± 8.14 |
| Heart Rate(beats/minute) | Low Dose DR-1031 | Midrange Dose DR-1031 | High Dose DR-1031 | Seasonale | Total |
|---|---|---|---|---|---|
| Mean | 73.9 ± 9.85 | 73.7 ± 8.90 | 73.7 ± 9.17 | 71.9 ± 9.07 | 73.3 ± 9.26 |
2 further baseline measures are reported on the registry.
The record gives a start of Oct 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 5 years 3 months after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol